heterotopic ossification

LDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2(IC50=1.3 nM) versus ALK1/3 compared to other inhibitors.

Prafnosbart (DS-6016A) is a humanized IgG1-kappa monoclonal antibody that specifically targets Activin A Receptor Type 1 (ACVR1/ALK2). By binding to ACVR1, Prafnosbart blocks the binding of Activin A and the subsequent abnormal activation of downstream SMAD1/5/8 signaling pathways, thereby inhibiting the formation of heterotopic ossification (HO). Prafnosbart is primarily used to investigate bone metabolic disorders associated with ACVR1 mutations, such as Fibrodysplasia Ossificans Progressiva (FOP).